Healthcare’s Assurance Infrastructure Is Broken. The Compliance Industry Built It That Way
SOC 2, HITRUST, and BAAs should be treated as starting points, not trust signals. They…
Healthcare’s Assurance Infrastructure Is Broken. The Compliance Industry Built It That Way
SOC 2, HITRUST, and BAAs should be treated as starting points, not trust signals. They tell you what a vendor claims about its controls. They do not tell you whether those controls are actually working today or whether the evidence behind the attestation was real. The post Healthcare’s Assurance Infrastructure Is Broken. The Compliance Industry…
Bridging Movement and Machine Learning: How Clinicians Can Harness AI in Practice
The true promise of AI lies not in autonomy of either the clinician or machine, but in a balanced collaboration that bolsters the strengths of each. The post Bridging Movement and Machine Learning: How Clinicians Can Harness AI in Practice appeared first on MedCity News.
GLP-1s Are a $70 Billion Market — So Why Are Patients Still Getting Medical Advice From TikTok Influencers?
It’s not hard to understand why patients turn to social media for GLP-1 guidance. The healthcare system leaves a huge gap between getting a prescription and actually understanding how to use it well. The post GLP-1s Are a $70 Billion Market — So Why Are Patients Still Getting Medical Advice From TikTok Influencers? appeared first…
What to Know About Recent Federal Actions Involving State Medicaid Program Integrity
This brief describes recent HHS actions (state-specific and nationwide) related to Medicaid program integrity and outlines some open questions about the future of Medicaid program integrity, including which states might become a focus of administration effort.
Trivia Nights, Valentine’s Cards: Overlooked Social Connections Can Prevent Suicide
If you or someone you know may be experiencing a mental health crisis, contact the 988 Suicide & Crisis Lifeline by dialing or texting “988.” Nearly every Tuesday for a decade, Steve Siple attended a bar trivia night with friends in Birmingham, Alabama. After moving to North Carolina, he developed a new ritual — joining…
Could Your Kid Benefit From Counseling? Experts Offer 3 Questions To Help You Decide
0:00 0:00 Produced in partnership with: Embed Download Volume Speed 0.5x 1x 1.25x 1.5x 2x Embed this player × <iframe src=”https://kffhealthnews.org/mental-health/healthq-children-therapy-experts-help-parents-decide/embed/” width=”600″ height=”200″ frameborder=”0″ scrolling=”no” title=”Could Your Kid Benefit From Counseling? Experts Offer 3 Questions To Help You Decide”></iframe> Copy HealthQ’s Cara Anthony and Blake Farmer share know-how for parents navigating the decision to seek…
Can AI Break the “Measurement Paradigm?”
How do we know if AI use in health care actually makes patients better? Chip talks with Dr. David Bates — a veteran physician leader at Mass General Brigham and the Brigham and Women’s Hospital and Co-director of the Center for Artificial Intelligence and Bioinformatics Learning Systems — about measuring patient outcomes reliably and in…
Why don’t health plans voluntarily cover GLP-1s for obesity?
ICER found GLP-1 drugs to be cost effective for treating obesity. If that is the case, why don’t more US payers cover the GLP-1 drugs? Clearly, one reason is the cost given the sheer volume of patients i nthe US that are obese; specifically, >40% of US adults are obese. However, a bigger issue may…
HHS Affordability Czar Says Healthcare Costs Stem From Incentives, Not Coverage
Healthcare affordability czar Casey Mulligan laid out the economic philosophy guiding the Trump administration’s approach to healthcare costs during a recent conference address. He argued that provider taxes and state-directed payments inflate healthcare spending far beyond Medicaid and ultimately raise costs for employers and taxpayers. The post HHS Affordability Czar Says Healthcare Costs Stem From…
Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug
Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing advantage compared to currently available therapies for von Willebrand disease, an inherited bleeding disorder. The deal comes as patent expiration looms for Jakafi, currently Incyte’s top product. The post Incyte’s $1.25B Buyout Brings What Could Become the…
